Mechanism — research framing

• GIP pathway: Discussed in publications regarding incretin and energy-balance research models.
• GLP-1 pathway: Commonly studied for satiety and glycemic dynamics in preclinical work.
• Glucagon pathway: Literature explores hepatic and energy-expenditure angles versus single-path agonists.

Areas of research interest (literature)

• Metabolic and obesity-related physiology — trial readouts are summarized in peer-reviewed sources, not on this page as medical guidance.
• Type 2 diabetes and glycemic endpoints — research-only discussion in qualified settings.
• Hepatic steatosis / MASH research narratives — investigational context only.
• Cardiometabolic risk markers — as reported in study populations, not as outcomes for purchase decisions.

Peptide regulations & site policy

• RUO: Materials are sold for research use only. They are not drugs, supplements, or cosmetics for human or animal use unless your program holds all required authorizations.
• FDA / FTC: Investigational compounds are not FDA-approved for the uses discussed in lay media. This page is educational; it does not diagnose, treat, cure, or prevent any disease.
• No clinical instructions: NEXT does not provide dosing, reconstitution for injection in humans, cycle advice, or prescribing information.
• Jurisdiction: Import, possession, and use of research peptides are regulated differently by country and state. You are responsible for lawful conduct in your location.
• COA & chain of custody: Batch documentation is provided per catalog policy; storage, handling, and record-keeping are your laboratory’s responsibility.
• Wholesale / retail paths: Volume and institutional purchasing follow B2B membership rules after approval; retail checkout follows discount membership and storefront terms.